Shuttle Pharmaceuticals Holdings (SHPH) Gains from Sales and Divestitures (2022 - 2026)

Shuttle Pharmaceuticals Holdings' Gains from Sales and Divestitures history runs 5 years deep, the most recent figure standing at $44766.0 for Q1 2026.

• In Q1 2026, Gains from Sales and Divestitures fell 94.67% year-over-year to $44766.0; the TTM figure through Mar 2026 stood at $44766.0 (down 94.67% YoY), while the FY2025 annual figure was $48747.0, up 62.51% from the prior year.
• Gains from Sales and Divestitures was $44766.0 for Q1 2026 at Shuttle Pharmaceuticals Holdings, down from $48747.0 in the prior quarter.
• In the past five years, Gains from Sales and Divestitures ranged from a high of $840205.0 in Q1 2025 to a low of $3500.0 in Q4 2022.
• Historically, Gains from Sales and Divestitures has averaged $97256.6 across 5 years, with a median of $39389.5 in 2025.
• The sharpest annual moves came in 2025 and 2026: Gains from Sales and Divestitures jumped 5277.31% in 2025, then sank 94.67% in 2026.
• A 5-year view of Gains from Sales and Divestitures shows it stood at $3500.0 in 2022, then jumped by 204.29% to $10650.0 in 2023, then surged by 181.66% to $29997.0 in 2024, then surged by 62.51% to $48747.0 in 2025, then declined by 8.17% to $44766.0 in 2026.
• The last three Gains from Sales and Divestitures figures came in at $44766.0 (Q1 2026), $48747.0 (Q4 2025), and $48747.0 (Q3 2025), per Business Quant data.